Ventricular Remodeling

• 

  Subject Areas on Research

  • A critical review of hemodynamic changes and left ventricular remodeling after surgical aortic valve replacement and percutaneous aortic valve replacement. 
  • A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. 
  • Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Assessment of no-reflow regions using cardiac MRI. 
  • Association between morning blood pressure surge and cardiovascular remodeling in treated elderly hypertensive subjects. 
  • Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 
  • Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. 
  • Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. 
  • Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Branch Pulmonary Artery Valve Implantation Reduces Pulmonary Regurgitation and Improves Right Ventricular Size/Function in Patients With Large Right Ventricular Outflow Tracts. 
  • Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cell size and communication: role in structural and electrical development and remodeling of the heart. 
  • Central sympathetic blockade ameliorates brain death-induced cardiotoxicity and associated changes in myocardial gene expression. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Circulating Concentrations of Orexin A Predict Left Ventricular Myocardial Remodeling. 
  • Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. 
  • Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. 
  • Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. 
  • Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. 
  • Controversies and Challenges of Ventricular Assist Device Therapy. 
  • Coronary bypass surgery with or without surgical ventricular reconstruction. 
  • Cross-sectional relations of lipid concentrations to left ventricular structural attributes. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. 
  • Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. 
  • Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. 
  • Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. 
  • Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. 
  • Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. 
  • Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. 
  • Electrical pacing counteracts intrinsic shortening of action potential duration of neonatal rat ventricular cells in culture. 
  • Electrophysiological effects of remodeling cardiac gap junctions and cell size: experimental and model studies of normal cardiac growth. 
  • Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. 
  • Emerging Therapies for Congestive Heart Failure. 
  • Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. 
  • Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. 
  • Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. 
  • FGF23 modifies the relationship between vitamin D and cardiac remodeling. 
  • Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. 
  • Found in translation soluble ST2 and heart disease. 
  • Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Galectin-3 expression in cardiac remodeling after myocardial infarction. 
  • Gender differences in molecular remodeling in pressure overload hypertrophy. 
  • Gender differences in postinfarction left ventricular remodeling. 
  • Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. 
  • Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. 
  • Genomics and the pathophysiology of heart failure. 
  • Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. 
  • Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. 
  • High-resolution imaging of murine myocardial infarction with delayed-enhancement cine micro-CT. 
  • High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. 
  • Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). 
  • Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. 
  • Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. 
  • Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. 
  • Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular remodeling following myocardial infarctions of varying size. 
  • Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Inhibition of the cardiomyocyte-specific troponin I-interacting kinase limits oxidative stress, injury, and adverse remodeling due to ischemic heart disease. 
  • Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. 
  • Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. 
  • Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Junctophilin-2 at the intersection of arrhythmia and pathologic cardiac remodeling. 
  • Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. 
  • Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Letter by Januzzi regarding article, "galectin-3 and cardiac function in survivors of acute myocardial infarction". 
  • Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. 
  • Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. 
  • Measures of cardiac repolarization and body position in infants. 
  • Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. 
  • MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression. 
  • Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. 
  • Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 
  • Modifying the mechanics of healing infarcts: Is better the enemy of good? 
  • Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. 
  • Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. 
  • Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction. 
  • Patterns of left ventricular remodeling in patients with Duchenne Muscular Dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. 
  • Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. 
  • Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. 
  • Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. 
  • Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. 
  • QRS fusion complex analysis using wave interference to predict reverse remodeling during cardiac resynchronization therapy. 
  • Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. 
  • Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). 
  • Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery. 
  • Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. 
  • Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. 
  • Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. 
  • Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. 
  • Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. 
  • Role of aldosterone receptor antagonist eplerenone in aortic stenosis. 
  • SRC-2 coactivator deficiency decreases functional reserve in response to pressure overload of mouse heart. 
  • ST2: a novel biomarker for heart failure. 
  • ST2: a novel remodeling biomarker in acute and chronic heart failure. 
  • Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated? 
  • Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. 
  • Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. 
  • Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. 
  • Simple regional strain pattern analysis to predict response to cardiac resynchronization therapy: rationale, initial results, and advantages. 
  • Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice. 
  • Spironolactone alleviates late cardiac remodeling after left ventricular restoration. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Surgical treatment of moderate ischemic mitral regurgitation. 
  • Surrogate end points in heart failure trials. 
  • The Effect of the Superior Cavopulmonary Anastomosis on Ventricular Remodeling in Infants with Single Ventricle. 
  • The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. 
  • The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. 
  • The STICH trial: evidence-based conclusions. 
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. 
  • The nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) increases free radical generation and degrades left ventricular function after myocardial ischemia-reperfusion. 
  • The perplexing complexity of cardiac arrhythmias: beyond electrical remodeling. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. 
  • Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. 
  • Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. 
  • Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. 
  • Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. 
  • β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Radiology
  • Landstrom, Andrew Paul, Assistant Professor of Pediatrics, Cell Biology
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Milazzo Jr., Angelo Stephen, Associate Professor of Pediatrics, Pediatrics
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology